Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,894,976
  • Shares Outstanding, K 1,473,827
  • Annual Sales, $ 14,240 M
  • Annual Income, $ 1,591 M
  • EBIT $ 3,351 M
  • EBITDA $ 4,605 M
  • 60-Month Beta 0.79
  • Price/Sales 9.35
  • Price/Cash Flow 31.11
  • Price/Book 6.35

Options Overview Details

View History
  • Implied Volatility 19.93% ( -0.53%)
  • Historical Volatility 18.23%
  • IV Percentile 56%
  • IV Rank 26.31%
  • IV High 34.64% on 10/11/24
  • IV Low 14.68% on 08/13/24
  • Put/Call Vol Ratio 0.38
  • Today's Volume 2,219
  • Volume Avg (30-Day) 14,863
  • Put/Call OI Ratio 1.17
  • Today's Open Interest 198,020
  • Open Int (30-Day) 245,438

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.65
  • Number of Estimates 12
  • High Estimate 0.66
  • Low Estimate 0.64
  • Prior Year 0.55
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.64 +13.26%
on 10/30/24
91.60 -0.29%
on 11/21/24
+3.28 (+3.73%)
since 10/21/24
3-Month
78.53 +16.30%
on 08/23/24
91.60 -0.29%
on 11/21/24
+12.52 (+15.89%)
since 08/21/24
52-Week
53.93 +69.35%
on 12/05/23
91.60 -0.29%
on 11/21/24
+36.01 (+65.09%)
since 11/21/23

Most Recent Stories

More News
Five Top Heart Health Stocks to Buy Heading into 2025

Heart health statistics are startling. Not only is heart disease the leading cause of death in the United States, it also claims the life of one person every 33 seconds. Plus, the estimated global annual...

ABT : 116.62 (+0.60%)
BSX : 91.44 (+1.41%)
CRDL : 1.5100 (-3.21%)
GILD : 89.66 (+1.16%)
MDT : 85.00 (+1.06%)
Top Analyst Reports for UnitedHealth, Bank of America & SAP

Wednesday, November 13, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth...

SONY : 19.10 (-0.42%)
SAP : 236.08 (+0.45%)
BAC : 46.78 (+1.56%)
BSX : 91.44 (+1.41%)
UNH : 601.11 (+0.10%)
SNY : 47.87 (+0.19%)
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours

Alcon, Inc. ALC delivered core earnings per share (EPS) of 81 cents for the third quarter of 2024, up 22.7% from the year-ago quarter’s figure (up 25% at the constant exchange rate or CER). The figure...

DGX : 163.03 (+1.06%)
BSX : 91.44 (+1.41%)
RMD : 242.08 (+0.22%)
ALC : 85.53 (+0.04%)
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues

Zimmer Biomet's ZBH strategic product launches and stabilizing market trends bolster our confidence in this stock. Yet, factors like macroeconomic uncertainties put pressure on the bottom line. The stock...

ZBH : 108.78 (-0.45%)
GMED : 84.58 (+1.18%)
BSX : 91.44 (+1.41%)
RMD : 242.08 (+0.22%)
Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy?

Medtronic plc MDT is scheduled to report second-quarter fiscal 2025 results on Nov. 19, before the opening bell.In the last reported quarter, the company’s adjusted earnings of $1.23 exceeded the Zacks...

ABT : 116.62 (+0.60%)
BSX : 91.44 (+1.41%)
MDT : 85.00 (+1.06%)
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins

Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.81 in the fourth quarter of fiscal 2024, up 11.4% year over year. The figure topped the Zacks...

DGX : 163.03 (+1.06%)
BSX : 91.44 (+1.41%)
BDX : 225.47 (+1.38%)
RMD : 242.08 (+0.22%)
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up

QIAGEN N.V.’s QGEN third-quarter 2024 adjusted earnings per share (EPS) were 57 cents, 58 cents at the constant exchange rate (CER). The reported figure increased 14% from the 2023 comparable figure...

DGX : 163.03 (+1.06%)
BSX : 91.44 (+1.41%)
QGEN : 42.30 (+0.50%)
ISRG : 549.78 (+1.47%)
CVS Health Q3 Earnings & Revenues Beat, Stock Rises in Premarket

CVS Health Corporation CVS posted adjusted earnings per share (EPS) of $1.09 in the third quarter of 2024, down 50.7% year over year. However, the metric topped the Zacks Consensus Estimate by 1.2%. The...

CVS : 56.96 (+0.23%)
DGX : 163.03 (+1.06%)
BSX : 91.44 (+1.41%)
ISRG : 549.78 (+1.47%)
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up

Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share....

DGX : 163.03 (+1.06%)
BSX : 91.44 (+1.41%)
CTLT : 59.78 (+1.32%)
RMD : 242.08 (+0.22%)
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in the year-ago quarter. The figure was wider than the Zacks Consensus Estimate...

DGX : 163.03 (+1.06%)
EXAS : 53.76 (+2.01%)
BSX : 91.44 (+1.41%)
ISRG : 549.78 (+1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and...

See More

Key Turning Points

3rd Resistance Point 92.17
2nd Resistance Point 91.49
1st Resistance Point 90.83
Last Price 91.45
1st Support Level 89.49
2nd Support Level 88.81
3rd Support Level 88.15

See More

52-Week High 91.60
Last Price 91.44
Fibonacci 61.8% 77.21
Fibonacci 50% 72.76
Fibonacci 38.2% 68.32
52-Week Low 53.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar